Search

Your search keyword '"Uro-Coste E"' showing total 383 results
Start Over Author "Uro-Coste E"
383 results on '"Uro-Coste E"'

2. Impact of facial nerve resection in parotid cancer abutting the facial nerve without preoperative paralysis: A multicentric propensity score-based analysis

Author

Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Bettoni, J., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Bozorg Grayeli, A., Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Classe, M., Clatot, F., Colin, E., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Espitalier, F., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F.R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Lacau Saint Guily, J., Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Lasne Cardon, A., Le Tourneau, C., Lefebvre, G., Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A., Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Pham Dang, N., Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., Prades, J.-M., Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., Thariat, J., Timar David, M., Timochenko, A., Toussaint, B., Uro Coste, E., Valette, G., Van den Abbeele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., Wong, S., Chatelet, Florian, Chevret, Sylvie, Fakhry, Nicolas, Even, Caroline, Malard, Olivier, de Monès, Erwan, Saroul, Nicolas, Mouawad, François, de Boutray, Marie, Mauvais, Olivier, Vergez, Sébastien, Evrard, Diane, Righini, Christian, Schultz, Philippe, Baudouin, Robin, Poissonnet, Gilles, Atallah, Sarah, Haroun, Fabienne, Morinière, Sylvain, Evrard, Camille, Philouze, Pierre, Paasche, Agnès, Lesnik, Maria, Lelonge, Yann, Herman, Philippe, and Verillaud, Benjamin

Published
2024
Full Text
View/download PDF

3. Mortalité : comparaison, causes et déterminants dans les sous-groupes de myopathies inflammatoires idiopathiques suivies dans la cohorte MIIRTALITY

Author

Larrauffie, A., primary, Bost, C., additional, Faruch-Bilfeld, M., additional, Uro-Coste, E., additional, Prevot, G., additional, Piel-Julian, M.L., additional, Cougoul, P., additional, Zordan, J., additional, Barrier, C., additional, Mourguet, M., additional, De Almeida Chaves, S., additional, Maquet, J., additional, Guille, M., additional, Sailler, L., additional, Moulis, G., additional, Alric, L., additional, and Pugnet, G., additional

Published
2024
Full Text
View/download PDF

10. Molecular and clinical diversity in primary central nervous system lymphoma

Author

Hernández-Verdin, I., Kirasic, E., Wienand, K., Mokhtari, K., Eimer, S., Loiseau, H., Rousseau, A., Paillassa, J., Ahle, G., Lerintiu, F., Uro-Coste, E., Oberic, L., Figarella-Branger, D., Chinot, O., Gauchotte, G., Taillandier, L., Marolleau, J.-P., Polivka, M., Adam, C., Ursu, R., Schmitt, A., Barillot, N., Nichelli, L., Lozano-Sánchez, F., Ibañez-Juliá, M.-J., Peyre, M., Mathon, B., Abada, Y., Charlotte, F., Davi, F., Stewart, C., de Reyniès, A., Choquet, S., Soussain, C., Houillier, C., Chapuy, B., Hoang-Xuan, K., Alentorn, A., Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University Medical Center Göttingen (UMG), Freie Universität Berlin, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de pathologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, CHU Bordeaux [Bordeaux], Imagerie moléculaire et thérapies innovantes en oncologie (IMOTION), Université de Bordeaux (UB), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Service de Neurologie [Hôpitaux Civils de Colmar], Hôpitaux Civils Colmar, Hôpitaux Civils de Colmar, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666 (HEMATIM), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Paris Diderot - Paris 7 (UPD7), Hopital Saint-Louis [AP-HP] (AP-HP), Institut Bergonié [Bordeaux], UNICANCER, Sorbonne Université (SU), Centre Hospitalier Saint Jean de Perpignan, Broad Institute of MIT and Harvard (BROAD INSTITUTE), Harvard Medical School [Boston] (HMS)-Massachusetts Institute of Technology (MIT)-Massachusetts General Hospital [Boston], Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Institut Curie - Saint Cloud (ICSC), DESSAIVRE, Louise, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’Anatomie Pathologique [CHRU Nancy], and École pratique des hautes études (EPHE)

Subjects
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Oncology, tumor heterogeneity, Hematology, multi-omics, microenvironment, PCNSL, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and distinct entity within diffuse large B-cell lymphoma presenting with variable response rates probably to underlying molecular heterogeneity.To identify and characterize PCNSL heterogeneity and facilitate clinical translation, we carried out a comprehensive multi-omic analysis [whole-exome sequencing, RNA sequencing (RNA-seq), methylation sequencing, and clinical features] in a discovery cohort of 147 fresh-frozen (FF) immunocompetent PCNSLs and a validation cohort of formalin-fixed, paraffin-embedded (FFPE) 93 PCNSLs with RNA-seq and clinico-radiological data.Consensus clustering of multi-omic data uncovered concordant classification of four robust, non-overlapping, prognostically significant clusters (CS). The CS1 and CS2 groups presented an immune-cold hypermethylated profile but a distinct clinical behavior. The 'immune-hot' CS4 group, enriched with mutations increasing the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and nuclear factor-κB activity, had the most favorable clinical outcome, while the heterogeneous-immune CS3 group had the worse prognosis probably due to its association with meningeal infiltration and enriched HIST1H1E mutations. CS1 was characterized by high Polycomb repressive complex 2 activity and CDKN2A/B loss leading to higher proliferation activity. Integrated analysis on proposed targets suggests potential use of immune checkpoint inhibitors/JAK1 inhibitors for CS4, cyclin D-Cdk4,6 plus phosphoinositide 3-kinase (PI3K) inhibitors for CS1, lenalidomide/demethylating drugs for CS2, and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitors for CS3. We developed an algorithm to identify the PCNSL subtypes using RNA-seq data from either FFPE or FF tissue.The integration of genome-wide data from multi-omic data revealed four molecular patterns in PCNSL with a distinctive prognostic impact that provides a basis for future clinical stratification and subtype-based targeted interventions.

Published
2023

14. OTHER NMDs

Author

Perrin, A., primary, Morales, R. Juntas, additional, Chapon, F., additional, Thèze, C., additional, Lacourt, D., additional, Pégeot, P., additional, Uro-Coste, E., additional, Giovannini, D., additional, Leboucq, N., additional, Mallaret, M., additional, Rigau, V., additional, Gaudon, K., additional, Richard, P., additional, Koenig, M., additional, Métay, C., additional, and Cossée, M., additional

Published
2021
Full Text
View/download PDF

15. OC-0333 Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial

Author

Laprie, A., primary, Noel, G., additional, Chaltiel, L., additional, Truc, G., additional, Sunyach, M., additional, Charissoux, M., additional, Magné, N., additional, Auberdiac, P., additional, Ken, S., additional, Roux, F., additional, Vieillevigne, L., additional, Tensaouti, F., additional, Catalaa, I., additional, Boetto, S., additional, Uro-Coste, E., additional, Supiot, S., additional, Bernier, V., additional, Filleron, T., additional, Mounier, M., additional, Poublanc, M., additional, Delord, J., additional, and Cohen-Jonathan-Moyal, E., additional

Published
2021
Full Text
View/download PDF

16. Essai interlaboratoire du réseau RENOCLIP : étude de concordance du statut CDKN2A dans les gliomes diffus, comparaison de quatre techniques immunohistochimiques et moléculaires

Author

Tauziede-Espariat, A., Rousseau, A., Basset, L., Saffroy, R., Cavillon, A., Lusque, A., Metais, A., Nicaise, Y., Uro-Coste, E., and Varlet, P.

Abstract

La délétion homozygote du gène CDKN2Aest un critère du grade 4 des astrocytomes diffus, IDH-mutés, quel que soit l’aspect morphologique. Plusieurs techniques moléculaires et immunohistochimiques sont utilisées en routine mais aucune étude de comparaison interlaboratoire n’a été publiée à ce jour pour les gliomes diffus.

Published
2024
Full Text
View/download PDF

17. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

Author

Alhalabi, K.T. Stichel, D. Sievers, P. Peterziel, H. Sommerkamp, A.C. Sturm, D. Wittmann, A. Sill, M. Jäger, N. Beck, P. Pajtler, K.W. Snuderl, M. Jour, G. Delorenzo, M. Martin, A.M. Levy, A. Dalvi, N. Hansford, J.R. Gottardo, N.G. Uro-Coste, E. Maurage, C.-A. Godfraind, C. Vandenbos, F. Pietsch, T. Kramm, C. Filippidou, M. Kattamis, A. Jones, C. Øra, I. Mikkelsen, T.S. Zapotocky, M. Sumerauer, D. Scheie, D. McCabe, M. Wesseling, P. Tops, B.B.J. Kranendonk, M.E.G. Karajannis, M.A. Bouvier, N. Papaemmanuil, E. Dohmen, H. Acker, T. von Hoff, K. Schmid, S. Miele, E. Filipski, K. Kitanovski, L. Krskova, L. Gojo, J. Haberler, C. Alvaro, F. Ecker, J. Selt, F. Milde, T. Witt, O. Oehme, I. Kool, M. von Deimling, A. Korshunov, A. Pfister, S.M. Sahm, F. Jones, D.T.W.

Abstract

Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens. © 2021, The Author(s).

Published
2021

18. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

Author

Alhalabi, KT, Stichel, D, Sievers, P, Peterziel, H, Sommerkamp, AC, Sturm, D, Wittmann, A, Sill, M, Jaeger, N, Beck, P, Pajtler, KW, Snuderl, M, Jour, G, Delorenzo, M, Martin, AM, Levy, A, Dalvi, N, Hansford, JR, Gottardo, NG, Uro-Coste, E, Maurage, C-A, Godfraind, C, Vandenbos, F, Pietsch, T, Kramm, C, Filippidou, M, Kattamis, A, Jones, C, Ora, I, Mikkelsen, TS, Zapotocky, M, Sumerauer, D, Scheie, D, McCabe, M, Wesseling, P, Tops, BBJ, Kranendonk, MEG, Karajannis, MA, Bouvier, N, Papaemmanuil, E, Dohmen, H, Acker, T, von Hoff, K, Schmid, S, Miele, E, Filipski, K, Kitanovski, L, Krskova, L, Gojo, J, Haberler, C, Alvaro, F, Ecker, J, Selt, F, Milde, T, Witt, O, Oehme, I, Kool, M, von Deimling, A, Korshunov, A, Pfister, SM, Sahm, F, Jones, DTW, Alhalabi, KT, Stichel, D, Sievers, P, Peterziel, H, Sommerkamp, AC, Sturm, D, Wittmann, A, Sill, M, Jaeger, N, Beck, P, Pajtler, KW, Snuderl, M, Jour, G, Delorenzo, M, Martin, AM, Levy, A, Dalvi, N, Hansford, JR, Gottardo, NG, Uro-Coste, E, Maurage, C-A, Godfraind, C, Vandenbos, F, Pietsch, T, Kramm, C, Filippidou, M, Kattamis, A, Jones, C, Ora, I, Mikkelsen, TS, Zapotocky, M, Sumerauer, D, Scheie, D, McCabe, M, Wesseling, P, Tops, BBJ, Kranendonk, MEG, Karajannis, MA, Bouvier, N, Papaemmanuil, E, Dohmen, H, Acker, T, von Hoff, K, Schmid, S, Miele, E, Filipski, K, Kitanovski, L, Krskova, L, Gojo, J, Haberler, C, Alvaro, F, Ecker, J, Selt, F, Milde, T, Witt, O, Oehme, I, Kool, M, von Deimling, A, Korshunov, A, Pfister, SM, Sahm, F, and Jones, DTW

Abstract

Large-scale molecular profiling studies in recent years have shown that central nervous system (CNS) tumors display a much greater heterogeneity in terms of molecularly distinct entities, cellular origins and genetic drivers than anticipated from histological assessment. DNA methylation profiling has emerged as a useful tool for robust tumor classification, providing new insights into these heterogeneous molecular classes. This is particularly true for rare CNS tumors with a broad morphological spectrum, which are not possible to assign as separate entities based on histological similarity alone. Here, we describe a molecularly distinct subset of predominantly pediatric CNS neoplasms (n = 60) that harbor PATZ1 fusions. The original histological diagnoses of these tumors covered a wide spectrum of tumor types and malignancy grades. While the single most common diagnosis was glioblastoma (GBM), clinical data of the PATZ1-fused tumors showed a better prognosis than typical GBM, despite frequent relapses. RNA sequencing revealed recurrent MN1:PATZ1 or EWSR1:PATZ1 fusions related to (often extensive) copy number variations on chromosome 22, where PATZ1 and the two fusion partners are located. These fusions have individually been reported in a number of glial/glioneuronal tumors, as well as extracranial sarcomas. We show here that they are more common than previously acknowledged, and together define a biologically distinct CNS tumor type with high expression of neural development markers such as PAX2, GATA2 and IGF2. Drug screening performed on the MN1:PATZ1 fusion-bearing KS-1 brain tumor cell line revealed preliminary candidates for further study. In summary, PATZ1 fusions define a molecular class of histologically polyphenotypic neuroepithelial tumors, which show an intermediate prognosis under current treatment regimens.

Published
2021

20. Wernicke encephalopathy and Creutzfeldt-Jakob disease

Author

Bertrand, A., Brandel, J. P., Grignon, Y., Sazdovitch, V., Seilhean, D., Faucheux, B., Privat, N., Brault, J. L., Vital, A., Uro-Coste, E., Pluot, M., Chapon, F., Maurage, C. A., Letournel, F., Vespignani, H., Place, G., Degos, C. F., Peoc’h, K., Haïk, S., and Hauw, J. J.

Published
2009
Full Text
View/download PDF

22. Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France

Author

Moya-Plana, A., primary, Aupérin, A., additional, Obongo, R., additional, Baglin, A., additional, Ferrand, F.R., additional, Baujat, B., additional, Saroul, N., additional, Casiraghi, O., additional, Vergez, S., additional, Herman, P., additional, Janot, F., additional, Thariat, J., additional, Vérillaud, B., additional, de Gabory, L., additional, Albert, S., additional, Andry, G., additional, Babin, E., additional, Bach, C., additional, Badet, J.-M., additional, Badoual, C., additional, Baglin, A.C., additional, Banal, A., additional, Barry, B., additional, Baudin, E., additional, Bensadoun, R.J., additional, Bertolus, C., additional, Bessède, J.-P., additional, Blanchard, D., additional, Borel, C., additional, Bozorg-Grayeli, A., additional, Breheret, R., additional, Breton, P., additional, Brugel, L., additional, Calais, G., additional, Cassagnau, E., additional, Castillo, L., additional, Ceruse, P., additional, Chabolle, F., additional, Chevalier, D., additional, Chobaut, J.C., additional, Choussy, O., additional, Cosmidis, A., additional, Coste, A., additional, Costes, V., additional, Crampette, L., additional, Darrouzet, V., additional, Demez, P., additional, Dessi, P., additional, Devauchelle, B., additional, Digue, L., additional, Dolivet, G., additional, Dubrulle, F., additional, Duflo, S., additional, Dufour, X., additional, Even, C., additional, Faivre, S., additional, Fakhry, N., additional, Ferron, C., additional, Floret, F., additional, Garrel, R., additional, Geoffrois, L., additional, Gilain, L., additional, Giovanni, A., additional, Girod, A., additional, Guerrier, B., additional, Hans, S., additional, Hofman, P., additional, Housset, M., additional, Jankowski, R., additional, Jegoux, F., additional, Juliéron, M., additional, Kaminsky, M.-C., additional, Kolb, F., additional, Lacau St Guily, J., additional, Laccoureye, L., additional, Lallemant, B., additional, Lang, P., additional, Lartigau, E., additional, Lavieille, J.-P., additional, Lefevre, M., additional, Leroy, X., additional, Malard, O., additional, Massip, F., additional, Mauvais, O., additional, Merol, J.-C., additional, Michel, J., additional, Mom, T., additional, Morinière, S., additional, de Monès, E., additional, Moulin, G., additional, Moya-Plana, A., additional, Noel, G., additional, Poissonnet, G., additional, Prades, J.-M., additional, de Raucourt, D., additional, Reyt, E., additional, Righini, C., additional, Marie Robin, Y., additional, Rolland, F., additional, Ruhin, B., additional, Sarroul, N., additional, Schultz, P., additional, Serrano, E., additional, Sterkers, O., additional, Strunski, V., additional, Sudaka, A., additional, Tassart, M., additional, Testelin, S., additional, Timochenko, A., additional, Toussaint, B., additional, Uro Coste, E., additional, Valette, G., additional, Van den Abbeele, T., additional, Varoquaux, A., additional, Veillon, F., additional, and Wassef, M., additional

Published
2019
Full Text
View/download PDF

28. P.237Functional analyses and phenotype-genotype correlation studies in patients suspected of titinopathy

Author

Juntas Morales, R., primary, Perrin, A., additional, Walther-Louvier, U., additional, Cintas, P., additional, Sole, G., additional, Espil, C., additional, Cances, C., additional, Renard, D., additional, Arne-Bes, M., additional, Rigau, V., additional, Maues de Paula, A., additional, Uro-coste, E., additional, Martine Negrier, M., additional, Leboucq, N., additional, Thorel, D., additional, Theze, C., additional, Pegeot, H., additional, Koenig, M., additional, and Cossee, M., additional

Published
2019
Full Text
View/download PDF

33. NEXT GENERATION SEQUENCING AND EXPERIMENTAL MYOLOGY

Author

Morales, R. Juntas, primary, Cances, C., additional, Cintas, P., additional, Renard, D., additional, Sole, G., additional, Espil, C., additional, Rivier, F., additional, Louvier, U. Walther, additional, Uro-Coste, E., additional, Perrin, A., additional, Leboucq, N., additional, Rigau, V., additional, Arne-Bes, M., additional, Duval, F., additional, Acket, B., additional, Peyroulan, D., additional, Theze, C., additional, Pegeot, H., additional, and Cossee, M., additional

Published
2018
Full Text
View/download PDF

36. Efficiency of next generation sequencing of a large panel of genes for diagnosis of children with myopathies and muscular dystrophies, especially for early and/or typical cases

Author

Lacourt, D., primary, Yauy, K., additional, Walther-Louvier, U., additional, Juntas-Morales, R., additional, Cances, C., additional, Espil, C., additional, Sole, G., additional, Arné-Bes, M., additional, Cintas, P., additional, Uro-coste, E., additional, Negrier, M. Martin, additional, Rigau, V., additional, Bieth, E., additional, Goizet, C., additional, Koenig, M., additional, Rivier, F., additional, and Cossée, M., additional

Published
2017
Full Text
View/download PDF

41. A case of laryngeal sialolipoma: pathology in focus

Author

Vairel, B., Woisard, V., Bonnecaze, G., Uro-Coste, E., and Sébastien Vergez

Subjects
Male, Humans, Lipoma, Vocal Cords, Laryngeal Neoplasms, Salivary Glands, Aged
Abstract

We are reporting a rare case of laryngeal sialolipoma in a 66-year-old male affected by Parkinson's disease. He was evaluated for dysarthria and swallowing disorders during which a swelling of the left ventricular fold, was always present and enlarged over a span of six months. Surgical removal of the left ventricular fold was performed. Microscopic examination, showed a circumscribed mass with organoid seromucous glands surrounded by numerous mature adipocytes, separated from the parenchyma and fatty tissue by dense fibrous tissue. This mass fulfilled the diagnostic criteria of sialolipoma. Sialolipomas can develop in a variety of sites in which there is both adipose and salivary gland tissue. To our knowledge, this is the first case of sialolipoma arising in the larynx.

Published
2014

42. Efficiency of targeted NGS on myopathies and muscular dystrophy genes: Importance of an optimized strategy of capture, sequencing, bioinformatic analyses and multidisciplinary approach for variants detection and interpretation

Author

Zenagui, R., primary, Lacourt, D., additional, Juntas-Morales, R., additional, Sole, G., additional, Cances, C., additional, River, F., additional, Renard, D., additional, Walther-Louvier, U., additional, Ferrer-Monasterio, X., additional, Espil, C., additional, Arné-Bes, M., additional, Cintas, P., additional, Uro-Coste, E., additional, Martin Negrier, M., additional, Rigau, V., additional, Bieth, E., additional, Goizet, C., additional, Claustres, M., additional, Koenig, M., additional, and Cossee, M., additional

Published
2016
Full Text
View/download PDF

49. Place du curage ganglionnaire avant radiothérapie exclusive dans la prise en charge des carcinomes épidermoïdes localement évolués des voies aérodigestives supérieures

Author

Modesto, A., primary, Sarini, J., additional, Benlyazid, A., additional, Ouali, M., additional, Laprie, A., additional, Graff, P., additional, Vergez, S., additional, Uro-Coste, E., additional, Fauquet, I., additional, Delord, J.-P., additional, and Rives, M., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results